BioCardia Inc BCDA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BCDA is a good fit for your portfolio.
News
-
BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results
-
BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024
-
BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership
-
BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study
-
BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure
-
BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA
-
BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference
-
BioCardia Shares Double After FDA Approves CardiAMP Trial
Trading Information
- Previous Close Price
- $0.37
- Day Range
- $0.37–0.37
- 52-Week Range
- $0.32–2.92
- Bid/Ask
- $0.37 / $0.37
- Market Cap
- $9.88 Mil
- Volume/Avg
- 19,801 / 370,366
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 16.33
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP® autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an “off the shelf” cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO™), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 20
- Website
- https://www.biocardia.com
Comparables
Valuation
|
Metric
|
BCDA
|
CBAY
|
OBIO
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 12.65 | 2.37 |
Price/Sales | 16.33 | 111.01 | 54.17 |
Price/Cash Flow | — | — | — |
Price/Earnings
BCDA
CBAY
OBIO
Financial Strength
|
Metric
|
BCDA
|
CBAY
|
OBIO
|
|---|---|---|---|
Quick Ratio | 0.32 | 10.70 | 7.82 |
Current Ratio | 0.40 | 10.96 | 7.95 |
Interest Coverage | — | −5.27 | — |
Quick Ratio
BCDA
CBAY
OBIO
Profitability
|
Metric
|
BCDA
|
CBAY
|
OBIO
|
|---|---|---|---|
Return on Assets (Normalized) | −169.92% | −30.06% | −35.16% |
Return on Equity (Normalized) | −828.20% | −51.97% | −51.40% |
Return on Invested Capital (Normalized) | −377.00% | −30.87% | −50.12% |
Return on Assets
BCDA
CBAY
OBIO
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Pfjdrzcmv | Jpp | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Pzkvqhqvv | Mmznzty | $103.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Hvltdckxp | Ksjhyg | $98.8 Bil | |
MRNA
| Moderna Inc | Btcqpchv | Wrtrd | $38.8 Bil | |
ARGX
| argenx SE ADR | Sljrvkfc | Jqqm | $21.3 Bil | |
BNTX
| BioNTech SE ADR | Mgfzsklh | Jxybh | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Zmftlttsk | Hjbpsz | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Pbtzwthgx | Dnpnpt | $17.0 Bil | |
RPRX
| Royalty Pharma PLC Class A | Kkbkggrnz | Skjllxv | $12.4 Bil | |
INCY
| Incyte Corp | Rdplpjch | Slwngsv | $11.9 Bil |